Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Recurrent Ovarian Cancer
NCT03206047Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian carcinoma, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) comparing Cohort I (atezolizumab), Cohort II (guadecitabine, atezolizumab) and Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine) (3 cohorts). Primary endpoints: Incidence of Adverse Events at 30 days and Progression Free Survival at 3 years. Started Nov 2017; status: terminated.
02
Drugs
atezolizumabguadecitabineCDX-1401
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03206047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206047.